Cargando…

Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial

BACKGROUND: Two large randomised trials of patients with well-differentiated thyroid cancer reported in 2012 (HiLo and ESTIMABL1) found similar post-ablation success rates at 6–9 months between a low administered radioactive iodine ((131)I) dose (1·1 GBq) and the standard high dose (3·7 GBq). Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Dehbi, Hakim-Moulay, Mallick, Ujjal, Wadsley, Jonathan, Newbold, Kate, Harmer, Clive, Hackshaw, Allan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Lancet, Diabetes & Endocrinology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299255/
https://www.ncbi.nlm.nih.gov/pubmed/30501974
http://dx.doi.org/10.1016/S2213-8587(18)30306-1

Ejemplares similares